NASDAQ:IMGNImmunoGen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.45 -0.04 (-1.15 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$3.34Now: $3.45▼$3.6350-Day Range$2.12MA: $3.87▼$6.8052-Week Range$1.76Now: $3.45▼$7.07Volume3.29 million shsAverage Volume3.41 million shsMarket Capitalization$601.41 millionP/E RatioN/ADividend YieldN/ABeta2.42 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.97, ImmunoGen has a potential upside of 73.0% from its current price of $3.45.Amount of Analyst CoverageImmunoGen has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesImmunoGen has received 433 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmunoGen has received 476 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmunoGen has received 52.37% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote “Outperform” if you believe IMGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $460,322.00 in company stock.Percentage Held by InsidersOnly 3.77% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions67.55% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow by 10.45% in the coming year, from ($0.67) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMGN Previous Symbol CUSIP45253H10 CIK855654 Webhttp://www.immunogen.com/ Phone781-895-0600Debt Debt-to-Equity RatioN/A Current Ratio2.70 Quick Ratio2.70Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$82.27 million Price / Sales7.31 Cash FlowN/A Price / Cash FlowN/A Book Value($0.51) per share Price / Book-6.76Profitability EPS (Most Recent Fiscal Year)($0.70) Net Income$-104,130,000.00 Net Margins-126.57% Return on EquityN/A Return on Assets-37.83%Miscellaneous Employees296 Outstanding Shares174,321,000Market Cap$601.41 million Next Earnings Date5/1/2020 (Estimated) OptionableOptionable Receive IMGN News and Ratings via Email Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IMGN Rates by TradingView ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions How has ImmunoGen's stock been impacted by COVID-19 (Coronavirus)? ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMGN shares have increased by 2.4% and is now trading at $3.45. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ImmunoGen? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ImmunoGen. When is ImmunoGen's next earnings date? ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for ImmunoGen. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Friday, February, 14th. The biotechnology company reported $0.03 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.08. The biotechnology company earned $44.86 million during the quarter, compared to analyst estimates of $29.24 million. View ImmunoGen's earnings history. What guidance has ImmunoGen issued on next quarter's earnings? ImmunoGen updated its FY 2020 Pre-Market earnings guidance on Friday, February, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $44.62 million. What price target have analysts set for IMGN? 4 equities research analysts have issued 12-month price objectives for ImmunoGen's shares. Their forecasts range from $2.94 to $9.00. On average, they expect ImmunoGen's share price to reach $5.97 in the next twelve months. This suggests a possible upside of 73.0% from the stock's current price. View analysts' price targets for ImmunoGen. Has ImmunoGen been receiving favorable news coverage? News articles about IMGN stock have trended very negative this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmunoGen earned a news impact score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutImmunoGen. Who are some of ImmunoGen's key competitors? Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Micron Technology (MU), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Gilead Sciences (GILD), Alibaba Group (BABA), Amarin (AMRN) and Nektar Therapeutics (NKTR). Who are ImmunoGen's key executives? ImmunoGen's management team includes the following people: Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)Mr. David G. Foster, VP of Fin. & Chief Accounting Officer What is ImmunoGen's stock symbol? ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN." How do I buy shares of ImmunoGen? Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ImmunoGen's stock price today? One share of IMGN stock can currently be purchased for approximately $3.45. How big of a company is ImmunoGen? ImmunoGen has a market capitalization of $601.41 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe. View additional information about ImmunoGen. What is ImmunoGen's official website? The official website for ImmunoGen is http://www.immunogen.com/. How can I contact ImmunoGen? ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: What are the benefits of momentum investing?
